New drug combo plus chemo for stomach cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (QLS31905 and QL2107) plus standard chemotherapy for stomach cancer that has spread and tests positive for a specific marker (CLDN18.2). It's for people who haven't had treatment yet, and the goal is to see if it shrinks tumors better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be stomach or gastroesophageal junction (where the stomach meets the food pipe) and can't be removed by surgery, or it has spread.
- You have not had any treatment for this stage of cancer before.
- You have at least one tumor that can be measured by imaging (like a CT scan).
- You haven't had severe allergic reactions to certain chemotherapy drugs (like oxaliplatin) or similar medicines.
- You haven't had another type of cancer within the last 5 years, and no serious bleeding in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.